Drug Target Prediction Based on the Herbs Components: The Study on the Multitargets Pharmacological Mechanism of Qishenkeli Acting on the Coronary Heart Disease

被引：59

作者：

Wang, Yong ^{[1
]}

Liu, Zhongyang ^{[2
]}

Li, Chun ^{[1
]}

Li, Dong ^{[2
]}

Ouyang, Yulin ^{[1
]}

Yu, Junda ^{[1
]}

Guo, Shuzhen ^{[1
]}

He, Fuchu ^{[2
]}

Wang, Wei ^{[1
]}

机构：

[1] Beijing Univ Chinese Med, Beijing, Peoples R China

[2] Beijing Proteome Res Ctr, Inst Radiat Med, State Key Lab Prote, Beijing 100850, Peoples R China

来源：

EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE | 2012年 / 2012卷

关键词：

ACTIVATION; FAILURE; PATHWAY; SYSTEM; GENES;

D O I：

10.1155/2012/698531

中图分类号：

R [医药、卫生];

学科分类号：

100218 [急诊医学];

摘要：

In this paper, we present a case study of Qishenkeli (QSKL) to research TCM's underlying molecular mechanism, based on drug target prediction and analyses of TCM chemical components and following experimental validation. First, after determining the compositive compounds of QSKL, we use drugCIPHER-CS to predict their potential drug targets. These potential targets are significantly enriched with known cardiovascular disease-related drug targets. Then we find these potential drug targets are significantly enriched in the biological processes of neuroactive ligand-receptor interaction, aminoacyl-tRNA biosynthesis, calcium signaling pathway, glycine, serine and threonine metabolism, and renin-angiotensin system (RAAS), and so on. Then, animal model of coronary heart disease (CHD) induced by left anterior descending coronary artery ligation is applied to validate predicted pathway. RAAS pathway is selected as an example, and the results show that QSKL has effect on both rennin and angiotensin II receptor (AT1R), which eventually down regulates the angiotensin II (AngII). Bioinformatics combing with experiment verification can provide a credible and objective method to understand the complicated multitargets mechanism for Chinese herbal formula.

引用

页数：10

共 39 条

[1]

The IntAct molecular interaction database in 2010 [J].